1
00:00:00,000 --> 00:00:05,083
For stroke research, the outcome you measure can change the headline.

2
00:00:05,083 --> 00:00:09,750
Cerebrolysin is a peptide mixture studied as an additional treatment.

3
00:00:09,750 --> 00:00:16,833
A 2023 Cochrane review found no convincing survival benefit and a possible increase in nonfatal serious

4
00:00:16,833 --> 00:00:20,333
adverse events. Those findings deserve attention.

5
00:00:20,333 --> 00:00:24,583
A later review reported improvement in early neurological scores.

6
00:00:24,583 --> 00:00:31,667
Different trial selections and endpoints help explain why the summaries differ; they do not settle every

7
00:00:31,667 --> 00:00:35,167
recovery question.

8
00:00:35,167 --> 00:00:39,042
Cerebrolysin is not FDA-approved in the United States.

9
00:00:39,042 --> 00:00:45,708
It should never be presented as a replacement for urgent stroke care or evidence-based rehabilitation.